FDA Early Alert: Teleflex/Arrow Guidewire

The U.S. Food and Drug Administration (FDA) has issued an Early Alert concerning a potentially high-risk quality issue affecting hydrophilic-coated guidewires manufactured by Arrow International, a subsidiary of Teleflex Incorporated. The issue involves Spring Wire Guide (SWG) components used in vascular access procedures. According to Teleflex, the hydrophilic coating may swell inconsistently when exposed to saline, causing the coating to clump and potentially detach. Detached coating material could enter the bloodstream and cause serious complications, including embolism, inflammation, thrombosis, ischemia, tissue injury, stroke, or death.

As of November 5, 2026, Arrow International had reported no serious injuries or deaths associated with the issue.

Which Devices Are Affected?

The affected products include Arrow hydrophilic-coated nitinol and stainless steel guidewires, along with several catheter products and kits containing the affected Spring Wire Guide components. They include configurations of:

• Arrow Marked Guidewire Hydrophilic-Coated Nitinol and Stainless Steel
• Pressure Injectable Arrowg+ard Blue Advance PICC and JACC products
• Arrowg+ard Blue Advance PICC kits with Arrow VPS Precision Stylet
• Pressure Injectable One-Lumen, Two-Lumen, and Three-Lumen PICC products

The affected configurations include multiple guidewire lengths and catheter arrangements. Healthcare facilities should consult the FDA’s complete affected-product list rather than relying solely on product family names to determine whether inventory is affected.

Why Coating Detachment Is Dangerous

Hydrophilic coatings are commonly used on guidewires and other intravascular devices to reduce friction and facilitate movement through blood vessels. However, these coatings must remain adequately attached throughout their intended use. If coating material separates from a guidewire, particles may enter the vascular system. Depending on particle size, distribution, and location, this material can obstruct blood vessels or trigger inflammatory reactions.

Hydrophilic polymer embolism is a recognized complication associated with intravascular devices. Potential consequences include vascular obstruction, tissue damage, and neurological injury. The reported defect is particularly concerning because it involves the coating’s behavior after hydration with saline, a routine step associated with preparing and using hydrophilic-coated guidewires.

Immediate Actions for Healthcare Facilities

On November 5, 2026, Arrow International notified affected customers and instructed them to take immediate action. Customers should:

1. Identify affected devices in their inventories.
2. Immediately discontinue use and distribution.
3. Quarantine affected products to prevent inadvertent use.
4. Contact Teleflex Customer Service to arrange product returns.
5. Forward the recall notification to customers who received affected products.

These instructions apply even though no serious injuries or deaths had been reported when the notification was issued.

Healthcare facilities should ensure that inventory controls and communication procedures prevent affected products from being returned to clinical use.

FDA Early Alert: What Does It Mean?

FDA’s Early Alert program provides timely public notification of potentially high-risk medical device problems while the agency continues evaluating available information. An Early Alert does not necessarily mean FDA has completed its assessment or assigned a formal recall classification. In this case, Teleflex has already initiated customer notification and product-removal activities, while FDA continues reviewing the issue.

The agency states that it will update its Early Alert as significant new information becomes available.

Regulatory and Quality-System Implications

The issue highlights the importance of coating integrity, supplier controls, and verification of device performance under conditions representative of actual clinical use.

For manufacturers of hydrophilic-coated intravascular devices, relevant quality considerations include material compatibility, coating adhesion, hydration behavior, particulate generation, and the potential consequences of coating separation. Where coated components are supplied by external manufacturers, purchasing controls and supplier qualification must address characteristics that could affect finished-device safety.

The reported problem also illustrates why component-level quality issues can affect multiple finished-device configurations and product families. A comprehensive investigation would need to determine the scope of affected components, the mechanism of coating failure, and whether existing design specifications, verification methods, manufacturing controls, and acceptance criteria adequately address the observed condition.

These are potential areas for investigation, not findings FDA has announced concerning Teleflex’s quality system. 

Reporting Problems and Obtaining Assistance

Healthcare professionals and consumers can report suspected adverse events or device-quality problems through FDA’s MedWatch reporting system.

Affected customers may contact Arrow International directly:

Email: Recalls@teleflex.com
Telephone: 1-866-396-2111

Additional information is available in Teleflex’s Field Safety Notice EIF-000614.

Patient Safety Remains the Priority

Although no serious injuries or deaths had been reported as of November 5, the potential consequences of hydrophilic coating detachment warrant immediate attention.

For healthcare facilities, the priority is identifying and removing affected devices before further use.

For manufacturers and suppliers, the alert reinforces a broader medical-device safety principle: the integrity of device coatings and components must be demonstrated under conditions that reflect how products are prepared and used clinically.